BUSINESS SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Business Segment Information [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. The determination of a single segment is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting future periods.

Product revenues and the composition of total revenues were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2017		2016		2017		2016
Prioritized Brands
Opdivo	$	1,265	$	920	$	3,587	$	2,464
Eliquis	1,232		884		3,509		2,395
Orencia	632		572		1,817		1,640
Sprycel	509		472		1,478		1,330
Yervoy	323		285		975		789
Empliciti	60		41		168		103
Established Brands
Hepatitis C Franchise	73		379		347		1,352
Baraclude	264		306		819		896
Sustiva Franchise	183		275		555		819
Reyataz Franchise	174		238		555		706
Other Brands	539		550		1,517		1,690
Total Revenues	$	5,254	$	4,922	$	15,327	$	14,184
Net product sales	$	4,862	$	4,492	$	14,212	$	12,888
Alliance revenues	334		402		957		1,229
Other revenues	58		28		158		67
Total Revenues	$	5,254	$	4,922	$	15,327	$	14,184